OBJECTIVES: The goal of this study was to investigate the association between natriuretic peptides and body fat distribution in a multiethnic cohort. BACKGROUND: Natriuretic peptides stimulate lipolysis, reduce weight gain, and promote adipocyte browning in animal models, but data are lacking in humans. METHODS: A total of 2,619 participants without heart failure in the Dallas Heart Study underwent measurements of 1) B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP); and 2) body fat distribution by dual energy x-ray absorptiometry and magnetic resonance imaging. Cross-sectional associations of natriuretic peptides with adiposity phenotypes were examined after adjustment for age, sex, race, comorbidities, and body mass index. RESULTS: Median BNP and NT-proBNP levels in the study cohort (mean age 44 years; 56% women, 48% African Americans, 32% obese) were 3.0 and 28.1 pg/ml, respectively. Natriuretic peptide levels above the median were associated with a more favorable body fat profile and less insulin resistance, including lower visceral fat, liver fat, and homeostasis model assessment of insulin resistance index, and increased lower body fat and higher adiponectin (p < 0.05 for each). In multivariable analyses, NT-proBNP remained inversely associated with visceral fat (beta coefficient = -0.08; p < 0.0001) and liver fat (beta coefficient = -0.14; p < 0.0001) and positively associated with lower body fat (beta coefficient = 0.07; p < 0.0001) independent of age, sex, race, and obesity status; findings were similar with BNP. Adjustment for body composition, homeostasis model assessment of insulin resistance index, circulating androgens, and adipocytokines did not attenuate the associations. CONCLUSIONS: Higher natriuretic peptide levels were independently associated with a favorable adiposity profile, characterized by decreased visceral and liver fat and increased lower body fat, suggesting a link between the heart and adipose tissue distribution mediated through natriuretic peptides.
OBJECTIVES: The goal of this study was to investigate the association between natriuretic peptides and body fat distribution in a multiethnic cohort. BACKGROUND: Natriuretic peptides stimulate lipolysis, reduce weight gain, and promote adipocyte browning in animal models, but data are lacking in humans. METHODS: A total of 2,619 participants without heart failure in the Dallas Heart Study underwent measurements of 1) B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP); and 2) body fat distribution by dual energy x-ray absorptiometry and magnetic resonance imaging. Cross-sectional associations of natriuretic peptides with adiposity phenotypes were examined after adjustment for age, sex, race, comorbidities, and body mass index. RESULTS: Median BNP and NT-proBNP levels in the study cohort (mean age 44 years; 56% women, 48% African Americans, 32% obese) were 3.0 and 28.1 pg/ml, respectively. Natriuretic peptide levels above the median were associated with a more favorable body fat profile and less insulin resistance, including lower visceral fat, liver fat, and homeostasis model assessment of insulin resistance index, and increased lower body fat and higher adiponectin (p < 0.05 for each). In multivariable analyses, NT-proBNP remained inversely associated with visceral fat (beta coefficient = -0.08; p < 0.0001) and liver fat (beta coefficient = -0.14; p < 0.0001) and positively associated with lower body fat (beta coefficient = 0.07; p < 0.0001) independent of age, sex, race, and obesity status; findings were similar with BNP. Adjustment for body composition, homeostasis model assessment of insulin resistance index, circulating androgens, and adipocytokines did not attenuate the associations. CONCLUSIONS: Higher natriuretic peptide levels were independently associated with a favorable adiposity profile, characterized by decreased visceral and liver fat and increased lower body fat, suggesting a link between the heart and adipose tissue distribution mediated through natriuretic peptides.
Authors: Thomas J Wang; Martin G Larson; Daniel Levy; Emelia J Benjamin; Eric P Leip; Peter W F Wilson; Ramachandran S Vasan Journal: Circulation Date: 2004-02-10 Impact factor: 29.690
Authors: Mandeep R Mehra; Patricia A Uber; Myung H Park; Robert L Scott; Hector O Ventura; Bobbett C Harris; Edward D Frohlich Journal: J Am Coll Cardiol Date: 2004-05-05 Impact factor: 24.094
Authors: Yuichiro Yano; Wanpen Vongpatanasin; Colby Ayers; Aslan Turer; Alvin Chandra; Mercedes R Carnethon; Philip Greenland; James A de Lemos; Ian J Neeland Journal: Hypertension Date: 2016-07-18 Impact factor: 10.190
Authors: Sanjiv J Shah; Dalane W Kitzman; Barry A Borlaug; Loek van Heerebeek; Michael R Zile; David A Kass; Walter J Paulus Journal: Circulation Date: 2016-07-05 Impact factor: 29.690
Authors: Jacob P Kelly; Robert J Mentz; Alexandre Mebazaa; Adriaan A Voors; Javed Butler; Lothar Roessig; Mona Fiuzat; Faiez Zannad; Bertram Pitt; Christopher M O'Connor; Carolyn S P Lam Journal: J Am Coll Cardiol Date: 2015-04-28 Impact factor: 24.094
Authors: Brian A Bergmark; Christopher P Cannon; William B White; Petr Jarolim; Yuyin Liu; Marc P Bonaca; Faiez Zannad; David A Morrow Journal: Diabetes Obes Metab Date: 2017-03-17 Impact factor: 6.577
Authors: Jeanney Lew; Monika Sanghavi; Colby R Ayers; Darren K McGuire; Torbjørn Omland; Dorothee Atzler; Maria O Gore; Ian Neeland; Jarett D Berry; Amit Khera; Anand Rohatgi; James A de Lemos Journal: Circulation Date: 2017-02-07 Impact factor: 29.690
Authors: O A Sanchez; D A Duprez; H Bahrami; C A Peralta; L B Daniels; J A Lima; A Maisel; A R Folsom; D R Jacobs Journal: Diabetes Metab Date: 2015-06-03 Impact factor: 6.041
Authors: Wendy Ying; Di Zhao; Pamela Ouyang; Vinita Subramanya; Dhananjay Vaidya; Chiadi E Ndumele; Kavita Sharma; Sanjiv J Shah; Susan R Heckbert; Joao A Lima; Christopher R deFilippi; Matthew J Budoff; Wendy S Post; Erin D Michos Journal: J Clin Endocrinol Metab Date: 2018-11-01 Impact factor: 5.958
Authors: Julie K Bower; Mariana Lazo; Kunihiro Matsushita; Jonathan Rubin; Ron C Hoogeveen; Christie M Ballantyne; Elizabeth Selvin Journal: Am J Hypertens Date: 2015-03-16 Impact factor: 2.689
Authors: Erika F Brutsaert; Mary L Biggs; Joseph A Delaney; Luc Djoussé; John S Gottdiener; Joachim H Ix; Francis Kim; Kenneth J Mukamal; David S Siscovick; Russell P Tracy; Ian H de Boer; Christopher R deFilippi; Jorge R Kizer Journal: Metabolism Date: 2016-06-24 Impact factor: 8.694